Skip to main content

Compare Stocks

Date Range: 

 Taysha Gene TherapiesPassage BioAdverum BiotechnologiesBlack Diamond TherapeuticsTCR2 Therapeutics
SymbolNASDAQ:TSHANASDAQ:PASGNASDAQ:ADVMNASDAQ:BDTXNASDAQ:TCRR
Price Information
Current Price$20.94$15.50$3.60$27.50$19.48
52 Week RangeBuyBuyHoldBuyBuy
MarketRank™
Overall Score1.81.81.81.61.8
Analysis Score3.53.44.13.54.5
Community Score4.03.32.32.72.6
Dividend Score0.00.00.00.00.0
Ownership Score0.81.72.51.71.7
Earnings & Valuation Score0.60.60.00.00.0
Analyst Ratings
Consensus RecommendationBuyBuyHoldBuyBuy
Consensus Price Target$43.92$27.32$14.13$51.50$45.14
% Upside from Price Target109.73% upside76.23% upside292.36% upside87.27% upside131.74% upside
Trade Information
Market Cap$793.98 million$836.64 million$352.57 million$994.46 million$742.91 million
BetaN/AN/A1.72N/A2.13
Average Volume85,355407,4221,826,546412,660501,345
Sales & Book Value
Annual RevenueN/AN/A$250,000.00N/AN/A
Price / SalesN/AN/A1,410.26N/AN/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book ValueN/AN/A$2.71 per share($1.44) per share$6.68 per share
Price / BookN/AN/A1.33N/AN/A
Profitability
Net IncomeN/AN/A$-64,490,000.00$-35,260,000.00$-47,600,000.00
EPSN/AN/A($1.01)($16.99)($4.62)
Trailing P/E Ratio0.000.00N/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/AN/A-32.23%-22.28%-35.51%
Return on Assets (ROA)N/AN/A-28.02%-17.91%-34.02%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/AN/A
Current Ratio24.02%18.30%28.53%29.67%32.38%
Quick Ratio24.02%18.30%28.53%29.66%32.38%
Ownership Information
Institutional Ownership Percentage42.19%67.59%97.41%65.78%82.05%
Insider Ownership PercentageN/AN/A12.40%N/A27.99%
Miscellaneous
Employees387416769118
Shares Outstanding37.92 million53.98 million97.94 million36.16 million38.14 million
Next Earnings Date8/10/2021 (Estimated)8/12/2021 (Estimated)8/9/2021 (Estimated)8/10/2021 (Estimated)N/A
OptionableNot OptionableNot OptionableOptionableNot OptionableNot Optionable
SourceHeadline
TCR2 Therapeutics (NASDAQ:TCRR) Posts  Earnings Results, Misses Expectations By $0.05 EPSTCR2 Therapeutics (NASDAQ:TCRR) Posts Earnings Results, Misses Expectations By $0.05 EPS
americanbankingnews.com - May 14 at 2:34 PM
TCR2 Therapeutics (NASDAQ:TCRR) PT Lowered to $45.00 at WedbushTCR2 Therapeutics (NASDAQ:TCRR) PT Lowered to $45.00 at Wedbush
americanbankingnews.com - May 14 at 11:16 AM
TCR2 Therapeutics (NASDAQ:TCRR) Coverage Initiated by Analysts at MizuhoTCR2 Therapeutics (NASDAQ:TCRR) Coverage Initiated by Analysts at Mizuho
americanbankingnews.com - May 13 at 12:54 PM
Axcella Health (NASDAQ:AXLA) and TCR2 Therapeutics (NASDAQ:TCRR) Critical SurveyAxcella Health (NASDAQ:AXLA) and TCR2 Therapeutics (NASDAQ:TCRR) Critical Survey
americanbankingnews.com - May 11 at 7:20 AM
TCR2 Therapeutics Inc. (NASDAQ:TCRR) Receives Consensus Rating of "Buy" from AnalystsTCR2 Therapeutics Inc. (NASDAQ:TCRR) Receives Consensus Rating of "Buy" from Analysts
americanbankingnews.com - May 8 at 1:45 AM
Forma Therapeutics (NASDAQ:FMTX) and TCR2 Therapeutics (NASDAQ:TCRR) Financial AnalysisForma Therapeutics (NASDAQ:FMTX) and TCR2 Therapeutics (NASDAQ:TCRR) Financial Analysis
americanbankingnews.com - May 5 at 8:46 AM
TCR2 Therapeutics (NASDAQ:TCRR) Shares Gap Down to $22.47TCR2 Therapeutics (NASDAQ:TCRR) Shares Gap Down to $22.47
americanbankingnews.com - May 4 at 11:06 AM
Zacks: Analysts Expect TCR2 Therapeutics Inc. (NASDAQ:TCRR) Will Post Earnings of -$0.55 Per ShareZacks: Analysts Expect TCR2 Therapeutics Inc. (NASDAQ:TCRR) Will Post Earnings of -$0.55 Per Share
americanbankingnews.com - April 30 at 2:38 PM
Tcr2 Therapeutics Inc (TCRR)Tcr2 Therapeutics Inc (TCRR)
investing.com - April 29 at 3:32 PM
TCR² Therapeutics to Present at the Truist Securities Life Sciences SummitTCR² Therapeutics to Present at the Truist Securities Life Sciences Summit
finance.yahoo.com - April 29 at 8:32 AM
Companies Like TCR2 Therapeutics (NASDAQ:TCRR) Are In A Position To Invest In GrowthCompanies Like TCR2 Therapeutics (NASDAQ:TCRR) Are In A Position To Invest In Growth
finance.yahoo.com - April 27 at 3:07 PM
TCRR May 2021 20.000 callTCRR May 2021 20.000 call
ca.finance.yahoo.com - April 23 at 12:06 AM
Can TCR2 Therapeutics Inc. (NASDAQ:TCRR) still be hot this week?Can TCR2 Therapeutics Inc. (NASDAQ:TCRR) still be hot this week?
stocksregister.com - April 17 at 6:01 PM
TCR² Highlights Gavo-cel Translational Data and Emerging Solid Tumor Pipeline Preclinical Data ...TCR² Highlights Gavo-cel Translational Data and Emerging Solid Tumor Pipeline Preclinical Data ...
apnews.com - April 10 at 1:23 PM
TCR² Highlights Gavo-cel Translational Data and Emerging Solid Tumor Pipeline Preclinical Data at AACR Annual MeetingTCR² Highlights Gavo-cel Translational Data and Emerging Solid Tumor Pipeline Preclinical Data at AACR Annual Meeting
finance.yahoo.com - April 10 at 1:22 PM
TCR² Therapeutics to Present at the Needham Healthcare ConferenceTCR² Therapeutics to Present at the Needham Healthcare Conference
finance.yahoo.com - April 8 at 7:11 AM
TCRR Jul 2021 35.000 callTCRR Jul 2021 35.000 call
ca.finance.yahoo.com - April 7 at 7:36 AM
TCR2 Therapeutics establishes cell therapy manufacturing facility in RockvilleTCR2 Therapeutics establishes cell therapy manufacturing facility in Rockville
thedailyrecord.com - March 29 at 6:23 PM
Is TCR2 Therapeutics Inc. (NASDAQ:TCRR) Dead in the Water?Is TCR2 Therapeutics Inc. (NASDAQ:TCRR) Dead in the Water?
stocksregister.com - March 29 at 1:23 PM
TCR2 Therapeutics Inc. [TCRR] stock Reiterated by H.C. Wainwright analyst, price target now $37TCR2 Therapeutics Inc. [TCRR] stock Reiterated by H.C. Wainwright analyst, price target now $37
dbtnews.com - March 29 at 1:23 PM
TCR² Therapeutics Establishes Commercial-Scale Cell Therapy Manufacturing FacilityTCR² Therapeutics Establishes Commercial-Scale Cell Therapy Manufacturing Facility
finance.yahoo.com - March 29 at 8:22 AM
TCR² Presentations at American Association of Cancer Research (AACR) Annual Meeting 2021 to ...TCR² Presentations at American Association of Cancer Research (AACR) Annual Meeting 2021 to ...
apnews.com - March 11 at 9:13 AM
TCR² Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides ...TCR² Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides ...
apnews.com - March 11 at 9:13 AM
TCR² Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate UpdateTCR² Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
finance.yahoo.com - March 11 at 9:13 AM
TCR² Presentations at American Association of Cancer Research (AACR) Annual Meeting 2021 to Highlight Solid Tumor PipelineTCR² Presentations at American Association of Cancer Research (AACR) Annual Meeting 2021 to Highlight Solid Tumor Pipeline
finance.yahoo.com - March 10 at 7:13 PM
DateCompanyBrokerageAction
4/26/2021Taysha Gene TherapiesChardan CapitalReiterated Rating
4/19/2021Taysha Gene TherapiesMorgan StanleyBoost Price Target
3/1/2021Taysha Gene TherapiesWilliam BlairInitiated Coverage
1/4/2021Taysha Gene TherapiesOppenheimerInitiated Coverage
10/19/2020Taysha Gene TherapiesJefferies Financial GroupInitiated Coverage
10/19/2020Taysha Gene TherapiesThe Goldman Sachs GroupInitiated Coverage
2/4/2021Passage BioGuggenheimInitiated Coverage
1/25/2021Passage BioWedbushInitiated Coverage
1/4/2021Passage BioJPMorgan Chase & Co.Upgrade
12/11/2020Passage BioSmith Barney CitigroupInitiated Coverage
12/11/2020Passage BioCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellInitiated Coverage
3/24/2020Passage BioCowenInitiated Coverage
5/10/2021Adverum BiotechnologiesSVB LeerinkReiterated Rating
5/5/2021Adverum BiotechnologiesRoyal Bank of CanadaReiterated Rating
5/5/2021Adverum BiotechnologiesTruist SecuritiesReiterated Rating
4/29/2021Adverum BiotechnologiesLifesci CapitalDowngrade
3/2/2021Adverum BiotechnologiesCantor FitzgeraldReiterated Rating
12/15/2020Adverum BiotechnologiesUBS GroupInitiated Coverage
11/12/2020Adverum BiotechnologiesRaymond JamesUpgrade
8/10/2020Adverum BiotechnologiesPiper SandlerBoost Price Target
3/26/2021Black Diamond TherapeuticsHC WainwrightReiterated Rating
1/19/2021Black Diamond TherapeuticsCanaccord GenuityReiterated Rating
11/24/2020Black Diamond TherapeuticsBerenberg BankInitiated Coverage
5/13/2021TCR2 TherapeuticsMizuhoInitiated Coverage
3/11/2021TCR2 TherapeuticsBMO Capital MarketsLower Price Target
11/30/2020TCR2 TherapeuticsRoth CapitalBoost Price Target
8/12/2020TCR2 TherapeuticsTruist FinancialInitiated Coverage
(Data available from 5/15/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.